Literature DB >> 17556674

Activity and inhibition resistance of a phospholipase-resistant synthetic surfactant in rat lungs.

Zhengdong Wang1, Yusuo Chang, Adrian L Schwan, Robert H Notter.   

Abstract

This study investigates the activity and inhibition resistance in excised rat lungs of a novel synthetic surfactant containing the phospholipase-resistant diether phosphonolipid DEPN-8 plus 1.5% bovine surfactant protein (SP)-B/C compared to calf lung surfactant extract (CLSE). DEPN-8 + 1.5% SP-B/C surpassed CLSE in normalizing surfactant-deficient pressure-volume (P-V) deflation mechanics in lavaged excised lungs in the presence of phospholipase A(2) (PLA(2)) or C18:1 lyso-phosphatidylcholine (LPC). DEPN-8 + 1.5% SP-B/C had activity equal to CLSE in normalizing P-V mechanics in the absence of inhibitors or in the presence of serum albumin. These physiologic activity findings were directly consistent with surface activity measurements on the pulsating bubble surfactometer. In the absence of inhibitors, DEPN-8 + 1.5% SP-B/C and CLSE rapidly reached minimum surface tensions < 1 mN/m (0.5 and 2.5 mg surfactant phospholipid/ml). DEPN-8 + 1.5% SP-B/C maintained its high surface activity in the presence of PLA(2), while the surface activity of CLSE was significantly inhibited by exposure to this enzyme. DEPN-8 + 1.5% SP-B/C also had greater surface activity than CLSE in the presence of LPC, and the two surfactants had equivalent surface activity in the presence of albumin. DEPN-8 + 1.5% SP-B/C also had slightly greater surface activity than CLSE when exposed to peroxynitrite in pulsating bubble studies. These results support the potential of developing highly active and inhibition-resistant synthetic exogenous surfactants containing DEPN-8 + apoprotein/peptide constituents for use in treating direct pulmonary forms of clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17556674      PMCID: PMC2176125          DOI: 10.1165/rcmb.2006-0434OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  57 in total

1.  A role for phospholipase A2 in ARDS pathogenesis.

Authors:  L Touqui; L Arbibe
Journal:  Mol Med Today       Date:  1999-06

2.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

Review 3.  Synthetic surfactant protein analogues.

Authors:  J Johansson; M Gustafsson; M Palmblad; S Zaltash; B Robertson; T Curstedt
Journal:  Biol Neonate       Date:  1998-09

4.  Instillation of calf lung surfactant extract (calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Members of the Mid-Atlantic Pediatric Critical Care Network.

Authors:  D F Willson; A Zaritsky; L A Bauman; K Dockery; R L James; D Conrad; H Craft; W E Novotny; E A Egan; H Dalton
Journal:  Crit Care Med       Date:  1999-01       Impact factor: 7.598

5.  Susceptibility of exogenous surfactant to phospholipase A2 degradation.

Authors:  J E Duncan; G M Hatch; J Belik
Journal:  Can J Physiol Pharmacol       Date:  1996-08       Impact factor: 2.273

6.  Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction.

Authors:  L Arbibe; K Koumanov; D Vial; C Rougeot; G Faure; N Havet; S Longacre; B B Vargaftig; G Béréziat; D R Voelker; C Wolf; L Touqui
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

7.  Multiple mechanisms of lung surfactant inhibition.

Authors:  B A Holm; Z Wang; R H Notter
Journal:  Pediatr Res       Date:  1999-07       Impact factor: 3.756

8.  Differential activity and lack of synergy of lung surfactant proteins SP-B and SP-C in interactions with phospholipids.

Authors:  Z Wang; O Gurel; J E Baatz; R H Notter
Journal:  J Lipid Res       Date:  1996-08       Impact factor: 5.922

9.  Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial.

Authors:  Douglas F Willson; Neal J Thomas; Barry P Markovitz; Loren A Bauman; Joseph V DiCarlo; Steven Pon; Brian R Jacobs; Larry S Jefferson; Mark R Conaway; Edward A Egan
Journal:  JAMA       Date:  2005-01-26       Impact factor: 56.272

10.  Additivity of protein and nonprotein inhibitors of lung surfactant activity.

Authors:  Z Wang; R H Notter
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

View more
  14 in total

1.  Synthesis and activity of a novel diether phosphonoglycerol in phospholipase-resistant synthetic lipid:peptide lung surfactants().

Authors:  Adrian L Schwan; Suneel P Singh; Jason A Davy; Alan J Waring; Larry M Gordon; Frans J Walther; Zhengdong Wang; Robert H Notter
Journal:  Medchemcomm       Date:  2011-10-19       Impact factor: 3.597

Review 2.  Cell wounding and repair in ventilator injured lungs.

Authors:  Richard A Oeckler; Rolf D Hubmayr
Journal:  Respir Physiol Neurobiol       Date:  2008-06-28       Impact factor: 1.931

Review 3.  Lung Contusion: A Clinico-Pathological Entity with Unpredictable Clinical Course.

Authors:  Farooq Ahmad Ganie; Hafeezulla Lone; Ghulam Nabi Lone; Mohd Lateef Wani; Shyam Singh; Abdual Majeed Dar; Nasir-U-Din Wani; Shadab Nabi Wani; Nadeem-Ul Nazeer
Journal:  Bull Emerg Trauma       Date:  2013-01

Review 4.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 5.  Lung contusion: inflammatory mechanisms and interaction with other injuries.

Authors:  Krishnan Raghavendran; Robert H Notter; Bruce A Davidson; Jadwiga D Helinski; Steven L Kunkel; Paul R Knight
Journal:  Shock       Date:  2009-08       Impact factor: 3.454

Review 6.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 7.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

8.  Tandem mass spectrometry of novel ether-linked phospholipid analogs of anionic pulmonary surfactant phospholipids.

Authors:  Rachel Fickes; Dennis R Voelker; Karin Zemski Berry; Robert C Murphy
Journal:  Rapid Commun Mass Spectrom       Date:  2016-12-30       Impact factor: 2.419

9.  Secretory phospholipase A2 and neonatal respiratory distress: pilot study on broncho-alveolar lavage.

Authors:  Daniele De Luca; Silvia Baroni; Giovanni Vento; Marco Piastra; Domenico Pietrini; Federica Romitelli; Ettore Capoluongo; Costantino Romagnoli; Giorgio Conti; Enrico Zecca
Journal:  Intensive Care Med       Date:  2008-07-22       Impact factor: 17.440

10.  Increased phospholipase A2 and lyso-phosphatidylcholine levels are associated with surfactant dysfunction in lung contusion injury in mice.

Authors:  David Machado-Aranda; Zhengdong Wang; Bi Yu; M V Suresh; Robert H Notter; Krishnan Raghavendran
Journal:  Surgery       Date:  2012-07-31       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.